HC Wainwright & Co. reiterates Buy rating on Immunocore Holdings, $100 price target
HC Wainwright & Co. maintained a Buy rating on Immunocore Holdings with a $100 price target, suggesting a 222.8% upside from the Oct 23 close of $30.98. The firm cited the company's strong pipeline, upcoming data releases, and established commercial footprint as key reasons for the rating.
How this was made

The 30-second read
Why it matters
The trading relevance is primarily sentiment and positioning around analyst expectations, not a fresh fundamental datapoint like trial results, approvals, or updated guidance.
Market read
For traders, the actionable element is the reiterated bullish target and catalyst narrative, which may marginally support the stock but lacks a new company-specific disclosure.
What to watch
Execution risk remains high for clinical-stage programs; the note’s emphasis on late-2026 data does not address probability of success, timelines, or competitive dynamics.
Background
The piece summarizes an HC Wainwright & Co analyst note reiterating a Buy rating for Immunocore and reiterating a $100 price target, with emphasis on its pipeline and KIMMTRAK/brenetafusp development.
Ticker impact
HC Wainwright reiterates a Buy on Immunocore and sets a $100 price target, citing pipeline strength and late-2026 data catalysts.
Likely modest upward bias as traders price in the reiterated Buy and target, though follow-through depends on upcoming clinical data.
The article is an analyst note reiteration, not a new trial result, approval, or guidance change; the main incremental input is the reiterated $100 target and thesis framing.
Market effects
Reinforces positive sentiment toward immuno-oncology/biotech pipeline narratives, but without new sector-wide data.
No clear regional macro or cross-market linkage beyond general biotech sentiment.
Limited global impact; the catalyst described is company-specific clinical timing rather than a worldwide regulatory or market event.
Counterpoint
A reiterated rating and price target may have limited incremental value if no new clinical readout or regulatory milestone is disclosed.
Key entities
- companyImmunocore Holdings
Subject of the analyst note reiteration, with a stated $100 price target and pipeline/catalyst thesis.
- analyst_firmHC Wainwright & Co.
Brokerage issuing the reiterated Buy rating and price target.